16 February 2011 in Neuropsychopharmacology
5 January 2012 in Journal of Neurochemistry
J. Neurochem. (2012) 120, 891–898. Chronic intake of high‐fat (HF) diet is known to alter brain neurotransmitter systems that participate in the central regulation of food intake. Dopamine (DA) system changes in response to HF diet have been observed in the hypothalamus, important in the homeostatic control of food intake, as well as within the central reward circuitry [ventral tegmental area (VTA), nucleus accumbens (NAc), and pre‐frontal cortex (PFC)], critical for coding the rewarding properties of palatable food and important in hedonically driven feeding behavior. Using a mouse model of diet‐induced obesity (DIO), significant alterations in the expression of DA‐related genes were documented in adult animals, and the general pattern of gene expression changes was opposite within the hypothalamus versus the reward circuitry (increased vs. decreased, respectively). Differential DNA methylation was identified within the promoter regions of tyrosine hydroxylase (TH) and dopamine transporter (DAT), and the pattern of this response was consistent with the pattern of gene expression. Behaviors consistent with increased hypothalamic DA and decreased reward circuitry DA were observed. These data identify differential DNA methylation as an epigenetic mechanism linking the chronic intake of HF diet with altered DA‐related gene expression, and this response varies by brain region and DNA sequence.
4 February 2010 in WIREs Mechanisms of Disease
1 October 2011 in American Journal of Obstetrics and Gynecology
21 May 2009 in Journal of Cellular Biochemistry
The diverse biological actions of retinoic acid (RA) are mediated by RA receptors (RARs) and retinoid X receptors (RXRs). While the coregulatory proteins that interact with the ligand‐dependent AF‐2 in the E region are well studied, the ligand‐independent N‐terminal AF‐1 domain‐interacting partners and their influence(s) on the function of RARs are poorly understood. HECT domain and Ankyrin repeat containing E3 ubiquitin–protein ligase (HACE1) was isolated as a RARβ3 AB region interacting protein. HACE1 interacts with RARβ3 both in in vitro GST pull‐down and in cell‐based coprecipitation assays. The interaction sites map to the N terminus of RARβ3 and the C terminus of HACE1. HACE1 functionally represses the transcriptional activity of RARα1, RARβ isoforms 1, 2, and 3, but not RARγ1 in luciferase reporter assays. In addition, HACE1 represses the endogenous RAR‐regulated genes CRABP II, RIG1 and RARβ2, but not RAI3 in CAOV3 cells. Mutation of the putative catalytic cysteine (C876 of LF HACE1), which is indispensable for its E3 ubiquitin ligase activity, does not alter the repressive effect of HACE1 on the transcriptional activity of RARβ3. On the other hand, HACE1 inhibits the RA dependent degradation of RARβ3. It is possible that the repression of RAR‐regulated transcription by HACE1 is due to its ability to inhibit the RA‐dependent degradation of RARs. J. Cell. Biochem. 107: 482–493, 2009.
8 December 2012 in Clinical Chemistry and Laboratory Medicine (CCLM)
Background: Quality control materials with minimal inter-assay differences and clinically relevant proportions of different molecular forms of the analyte are needed to optimize intra- and inter-laboratory accuracy and precision. Methods: We assessed if clinically relevant total prostate-specific antigen (tPSA) levels were present in seven commercially available Multi Constituent Tumor Marker Controls (MC-TMC). Further, we determined the concentration of free PSA (fPSA) and calculated the percentage of free PSA (%fPSA) in all materials. Finally, we determined variability of TMC materials across several commonly used PSA platforms. Results: All MC-TMC materials contained at least one concentration of tPSA in normal and pathologic range. Control materials varied in the amount of fPSA and %fPSA, with most controls consisting of fPSA only and only one MC-TMC containing medically relevant levels of around 35% fPSA. Only a minority of MC-TMC materials showed minimal variability across four PSA methods while the majority of PSA controls showed wide inter-method differences. Conclusions: Use of many commercially available controls for PSA could lead to biased PSA measurements because they contain medically irrelevant proportions of fPSA and show significant variation among different PSA assay platforms.